Determination of dextromethorphan metabolizer phenotype in healthy volunteers
- 1 January 1989
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 36 (3) , 315-318
- https://doi.org/10.1007/bf00558166
Abstract
The dextromethorphan metabolizer phenotype in 450 healthy volunteers (299 men, 151 women) was determined after oral administration of a 15 mg dose. In 8 h-postdose urine samples the ratio of dextrorphan (DOP) to dextromethorphan (DMP) was measured by HPLC. Urinary excretion of DMP and DOP within 8 h after the dose varied greatly between individuals, ranging from 0–11% and 0.04–100% of dose, respectively. In 143 test subjects the fraction of the dose of DMP in urine was below the detection limit. In the remaining 307 volunteers the metabolic ratio (MR) of DOP to DMP varied from 0.07 to 2906. In 404 test subjects the MR was >10 and they were classified as extensive metabolizers (90% of the entire group). Of the entire group 5% had MRs of 1–10 and <1, respectively. Depending on the limit for classification of poor metabolizers, their frequency was 5–10% in the Caucasian population studied. The present data are in agreement with previous findings that the oxidative metabolic polymorphisms of debrisoquin and DMP co-segregate; the frequency of the PM phenotype of dextromethorphan in Caucasian populations varies between 5 and 10%.Keywords
This publication has 19 references indexed in Scilit:
- Genetic variation in the human hepatic cytochrome P-450 systemEuropean Journal of Clinical Pharmacology, 1987
- Stereoselective pharmacokinetics of perhexilineXenobiotica, 1986
- Pharmacogenetics of dextromethorphan O-demethylation in manXenobiotica, 1986
- Human-liver cytochromes P-450 involved in polymorphisms of drug oxidationXenobiotica, 1986
- Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in manEuropean Journal of Clinical Pharmacology, 1984
- Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation.Journal of Clinical Investigation, 1983
- Genetically determined oxidation capacity and the disposition of debrisoquine.British Journal of Clinical Pharmacology, 1983
- Influence of the defective metabolism of sparteine on its pharmacokineticsEuropean Journal of Clinical Pharmacology, 1979
- Pharmacogenetics of tolbutamide metabolism in humansDiabetes, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977